In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chiesi to market uniQure’s Glybera, AMT060 in Europe and other regions; terminated

Executive Summary

Dutch biotech start-up uniQure BV has licensed Italian pharmaco Chiesi Farmaceutici SPA exclusive rights to market its orphan drug Glybera (alipogene tiparvovec) in Europe, Brazil, Mexico, Pakistan, Turkey, Russia, the CIS, and China. Chiesi also received an exclusive license to co-develop uniQure’s Phase I/II hemophilia B gene candidate AMT060 and sell it in the same territories, except China. UniQure retains rights to both medicines in the US, Japan, Australasia, and parts of Latin America and Asia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies